methyl[2-(pyridin-2-yl)ethyl]amine

• ChemBase编号: 4436
• 分子式: C8H12N2
• 平均质量: 136.19428
• 单一同位素质量: 136.10004839
• SMILES: CNCCc1ccccn1
• Canonical SMILES: CNCCc1ccccn1
• InChI: InChI=1S/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3
• InChIKey: UUQMNUMQCIQDMZ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: methyl[2-(pyridin-2-yl)ethyl]amine
• IUPAC传统名: betahistine; methyl[2-(pyridin-2-yl)ethyl]amine
• 商标名: Serc
• 别名: 2-(2-甲基氨基乙基)吡啶; Betahistine; N-Methyl-N-[2-(2-pyridyl)ethyl]amine; 2-[2-(Methylamino)ethyl]pyridine; N-methyl-N-[2-(2-pyridyl)ethyl]amine; 2-(2-Methylaminoethyl)pyridine; N-Methyl-2-pyridineethanamine Dihydrochloride; 2-[2-(Methylamino)ethyl]pyridine Dihydrochloride; Betaserc; PT 9; Serc; Sinmenier; Vasomotal; Betahistine Dihydrochloride; N-Methyl-2-(pyridin-2-yl)ethanamine; 2-(2-METHYLAMINOETHYL)PYRIDINE; N-Methyl-2-pyridineethanamine; Betahistine; Beta-Histine; Betahistine

登记号

• CAS号: 5579-84-0; 5638-76-6
• EC号: 227-086-4
• MDL号: MFCD00006362
• PubChem SID: 160967868; 24896774; 99443252
• PubChem CID: 2366
• CHEBI ID: 35677
• ATC码: N07CA01
• CHEMBL: 24441
• Chemspider ID: 2276
• DrugBank ID: DB06698
• KEGG ID: D07522
• 美国药典/FDA物质标识码: X32KK4201D
• 维基百科标题: Betahistine

理论计算性质

JChem

• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): -2.5812378
• LogD (pH = 7.4): -1.6845183
• Log P: 0.63240683
• 摩尔折射率: 41.3263 cm^3
• 极化性: 16.420544 Å^3
• 极化表面积: 24.92 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.59
• LOG S: -0.44
• 溶解度: 4.93e+01 g/l

分子性质

理化性质

• 溶解度: Water
• 外观: White Solid
• 熔点: 152-155°C
• 沸点: 113-114 °C/30 mmHg(lit.); 113-114°C/30mm
• 闪点: 206.6 °F; 97 °C
• 密度: 0.984 g/mL at 25 °C(lit.)
• 折射率: n20/D 1.518(lit.)

安全信息

• 保存条件: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• 保存注意事项: Corrosive
• RTECS编号: UT5552000
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 德国WGK号: 2
• 危险公开号: 36/37/38
• 安全公开号: 26-37/39
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H315-H319-H335
• GHS警示性声明: P261-P305 + P351 + P338
• 个人保护装置: Eyeshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter

药理学性质

• 给药途径: Oral
• 排泄: Renal
• 半衰期: 3–4 hours
• 代谢: To 2-(2-aminoethyl)pyridine and 2-pyridylacetic acid
• 蛋白结合率: Very low
• 法定药品分级: Rx-only (US)
• 生物活性机理: Diamine oxidase inhibitor

产品相关信息

• 纯度: 95+%; 97%
• 应用领域: Antihistamine; Has been used to treat the symptoms of Meacuteniegravere's disease; Used in treatment of circulatory diseases
• Empirical Formula (Hill Notation): C8H12N2

详细说明

MP Biomedicals - 05206493

MP Biomedicals Rare Chemical collection

DrugBank - DB06698

• Drug Groups: approved
• Description: Betahistine is an antivertigo drug first used for treating vertigo assosicated with Ménière's disease. It is also commonly used for patients with balance disorders.
• Indication: For the reduction of episodes of vertigo association with Ménière's disease.
• Pharmacology: Betahistine primarily acts as a histamine H1-agonist with 0.07 times the activity of histamine. Stimulating the H1-receptors in the inner ear causes a vasodilatory effect and increased permeability in the blood vessels which results in reduced endolymphatic pressure. Betahistine is believed to act by reducing the asymmetrical functioning of sensory vestibular organs as well as by increasing vestibulocochlear blood flow. Doing so aids in decreasing symptoms of vertigo and balance disorders.; Betahistine also acts as a histamine H3-receptor antagonist which causes an increased output of histamine from histaminergic nerve endings which can further increase the direct H1-agonist activity. Furthermore, H3-receptor antagonism increases the levels of neurotransmitters such as serotonin in the brainstem, which inhibits the activity of vestibular nuclei, helping to restore proper balance and decrease in vertigo symptoms.
• Toxicity: Symptoms of overdose (< 640 mg) include mild to moderate nausea, dry mouth, dyspepsia, abdominal pain and somnolence. More serious complications such as convulsions, pulmonary or cardiac complications, may occur with higher intentional overdoses (> 640 mg).
• Affected Organisms: Humans and other mammals
• Biotransformation: Betahistine is metabolized primarily into 2-pyridylacetic acid and is subsequently excreted in the urine.
• Absorption: When given orally, betahistine is rapidly absorbed from the gastrointestinal tract.
• Half Life: 3-4 hours
• Protein Binding: Very low.
• Elimination: Renal
• References: [Health Canada]
• External Links: Wikipedia

Sigma Aldrich - M28804

包装
5, 25 g in glass bottle
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. M28804.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Toronto Research Chemicals - B324001

Betahistine is most commonly used to treat the symptoms of Ménière's disease and vertigo. Vasodilator.

参考文献

• Health Canada
• Gilligan, P., et al.: J. Med. Chem., 43, 1641 (2000)
• Keller, P., et al.: Bioorg. Med. Chem., 8, 1213 (2000)
• Hauger, R., et al.: Pharmacol. Rev., 55, 21 (2000)
• Han, X., et al.: Bioorg. Med. Chem. Lett., 15, 3870 (2000)
• Aldrich Library of 13C and 1H FT NMR Spectra, 1992, 3, 290A, (nmr)
• Aldrich Library of FT-IR Spectra, 1st edn., 1985, 2, 764D; 765A, (ir)
• Aldrich Library of FT-IR Spectra: Vapor Phase, 1989, 3, 1535D, (ir)
• Lffler, K., Ber., 1904, 37, 161, (synth)
• Walter, L.A. et al., J.A.C.S., 1941, 63, 2771, (synth)
• Hunt, W.H. et al., J. Pharmacol., 1942, 75, 299, (pharmacol)
• Sternson, L. et al., Drug Metab. Dispos., 1974, 2, 123, (metab)
• Ger. Pat., 1974, 2 359 107; CA, 82, 57570, (synth, use)
• Sakamoto, T. et al., Chem. Pharm. Bull., 1984, 32, 4866, (synth)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 1341